The cancer therapy 'gold rush'

Summit and BioNTech results raise hope of new 'broad, pan-tumor platform' like Keytruda

January 24, 2025 Check out STAT+

Sponsored By

Adobe STAT+ | Cancer therapy's new 'gold rush': bispecific antibodies that hit key combination of targets Recent results with bispecific antibodies that target VEGF and PD-1 proteins raise hope of new "pan-tumor platform" like Keytruda. By Angus Chen STAT+ | What to watch on Akero's MASH-cirrhosis study results next month In this week's newsletter, we take a look at an upcoming readout from Akero Therapeutics and check in on the commercial launch of Madrigal's Rezdiffra. By Adam Feuerstein Trump administration's abrupt cancellation of scientific meetings prompts confusion, concern The scope of the cancellations was unclear, but researchers worried that NIH funding and scientific updates to the public could be affected. By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser